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Summary
Frontotemporal dementia is a term used to characterize
diverse neuropathological conditions that can present
with the same clinical phenotype. Five different neuro-
pathologies underlie this disorder. However, consistent
frontal and/or temporal neuronal loss and gliosis char-
acterize all cases, the majority having no obvious patho-
logical inclusions. Because neuronal loss and gliosis are
consistent features across all cases, the present study
aimed to determine the relationship between neuronal
loss, gliosis and, for cases with abnormal tau inclusions,
intracellular tau deposition. Formalin-®xed brain speci-
mens from sporadic cases with frontotemporal dementia
(eight with tau-positive Pick bodies, ®ve with fronto-
temporal lobar degeneration without inclusions) were
compared with those from non-diseased controls (n = 5).
Brain specimens were cut into 3 mm coronal slices for
evaluation and tissue samples from the superior frontal
gyrus were taken for microscopic analysis. Immuno-
histochemistry for glia-speci®c proteins (astrocytic glial
®brillary acidic protein and microglial major histocom-
patibility complex II) and different tau epitopes was
performed on 50 mm free-¯oating sections. Gross pat-
terns of brain atrophy were analysed and upper and
lower layer pyramidal neurons and glial cell numbers
were quanti®ed. A disease severity scheme was devised
using the degree of gross macroscopic frontal and
temporal atrophy to establish the relationship between
the gliosis and neurodegeneration. In this small sample,
the patterns of gross atrophy could be grouped reliably
into four stages of severity. These stages were the same
across disease groups and correlated with volume-
corrected pyramidal neuron densities. In cases with
Pick bodies, disease stage also correlated with duration,
providing further evidence that these stages represent
the progression of degeneration in this limited sample.
Whereas there were, on average, many more reactive
astrocytes in the cases with Pick bodies than in those
with frontotemporal lobar atrophy, there was signi®cant
overlap between cases in the degree of astrocytosis.
However, a large proportion of the astrocytes in Pick's
disease displayed phosphorylated tau immunoreactivity,
whereas no tau-positive astrocytes were found in fronto-
temporal lobar degeneration. The pattern and degree of
microglia activation were similar in all the dementia
cases analysed, with considerably more activated micro-
glia accumulating in white matter. In this small sample,
the abundance of white matter microglia at early
disease stages suggests a prominent role for this cell
type in the neurodegenerative process. In fronto-
temporal lobar degeneration, a signi®cant proportion of
the activated white matter microglia were tau-2-
immunoreactive, suggesting direct involvement in
axonal degeneration, possibly via immune processes.
Keywords: astrocytes; frontotemporal dementia; microglia; Pick's disease; tau
Abbreviations: FTD = frontotemporal dementia; FTLD = frontotemporal lobar degeneration; GFAP = glial ®brillary acidic
protein; HLA-DR = major histocompatibility antigen II; MSR = macrophage scavenger receptor antibody; PiD = Pick's
disease
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 Introduction
Frontotemporal dementia (FTD) is an insidious dementia
syndrome which usually presents with progressive changes in
behaviour, but may also present with progressive language
dysfunction (Hodges and Miller, 2001; McKhann et al.,
2001). The vast majority of cases have frontal and/or anterior
temporal lobar atrophy consistent with the pattern of neuronal
loss (Dickson, 1998; Mann, 1998; Neary et al., 1998;
Spillantini et al., 1998; Hodges and Miller, 2001). At autopsy
the degree of cerebral atrophy varies markedly in different
patients (Chan et al., 2001), suggesting considerable vari-
ability in the disease process. This variability is con®rmed by
the identi®cation of ®ve basic underlying histopathologies
(Hodges and Miller, 2001; McKhann et al., 2001): (i) cases
with neuronal inclusions with a predominance of insoluble 3-
repeat tau; the largest group have Pick's disease (PiD) with
tau-positive Pick bodies [usually sporadic (Morris et al.,
2001; Rossor, 1999)]; (ii) cases with neuronal inclusions with
a predominance of insoluble four-repeat tau; they have
familial FTD with tau gene mutations (Morris et al., 2001)
and sporadic corticobasal degeneration or progressive supra-
nuclear palsy (Bergeron et al., 1998); (iii) cases with neuronal
inclusions with insoluble three- and four-repeat tau; the
largest group of these have familial FTD with tau gene
mutations (Morris et al., 2001); (iv) cases lacking distinctive
intraneuronal inclusions; these cases have frontotemporal
lobar degeneration (FTLD), which can be sporadic or familial
(Mann, 1998; Morris et al., 2001); one family is linked to an
abnormality on chromosome 3 (Ashworth et al., 1999); (v)
cases with ubiquitin-positive and tau-negative neuronal
inclusions; these have FTLD with motor neuron disease or
with inclusions typical of motor neuron disease, which can be
sporadic or familial (Jackson et al., 1996; Morris et al., 2001);
one family is linked to an abnormality on chromosome 9
(Hosler et al., 2000). As can be seen, signi®cant advances
have been made concerning the molecular mechanisms of cell
death in FTD cases with intraneuronal inclusions. However,
the pathophysiology of FTLD is still poorly understood.
The major pathological change in FTLD is the substantial
gliosis associated with cell loss (Mann, 1998). Unlike other
degenerative diseases affecting the cortex, FTLD is also
characterized by substantial gliosis in the white matter
(Cooper et al., 1996; Kitagaki et al., 1997; Nichol et al.,
2001), as indicated by the descriptive diagnosis of progres-
sive subcortical gliosis in a proportion of cases (Mann, 1998).
Recent quantitation of the histological changes in FTLD
cases reveals signi®cantly more astrocytes and microglia in
the frontal cortices compared with controls (Arnold et al.,
2000; Martin et al., 2001). Arnold and colleagues suggest that
the microglia could be involved mechanistically in the cell
death as neuronal expression of microglia-speci®c antigens
are observed in the frontal and temporal cortices of some
cases (Hollister et al., 1997; Arnold et al., 2000). In
corticobasal degeneration and progressive supranuclear
palsy, signi®cant microglia activation has been shown to
correlate with the distribution and degree of neuronal tau
deposition (Ishizawa and Dickson, 2001). Of course, in these
disorders as well as in PiD, signi®cant tau deposition also
occurs in the cortical astroglia and oligodendroglia (Komori,
1999; Berry et al., 2001), with a suggestion that such tau
accumulation provides some protection for these cell types
(Ishizawa and Dickson, 2001). Overall, the data favour an
important role for microglia in the pathogenesis of FTLD and
PiD, whether in response to a neuronal immune stimulus
(FTLD; Arnold et al., 2000) or in response to neuronal tau
deposition (PiD; Komori, 1999). The present study evaluated
the relationship between microglial activation, neuronal loss
and tau deposition in FTLD compared with PiD. A role for
microglia in the pathogenesis of the disease can only be
inferred if activation is an early rather than a late event.
Material and methods
Cases
Five cases with FTLD and eight with PiD (Fig. 1) were
compared with ®ve control cases without neurological or
neuropathological disease. Brains were collected at routine or
brain-only autopsy through a regional brain donor pro-
gramme. The programme includes prospective clinical
evaluations of cases using consensus criteria, as recom-
mended recently (McKhann et al., 2001), and is approved by
the Ethics Committees of the South Eastern and Central
Sydney Areas Health Services and the Universities of Sydney
and New South Wales. All subjects were examined by a
neurologist or geriatrician and were assessed clinically within
12 months before death. Additional corroborative informa-
tion for each patient was obtained from an informant
interview to ascertain the pattern and type of de®cits, to aid
in the estimation of disease duration and obtain information
on any family history of disease. Cases with infarction, head
injury or any neurodegenerative disease other than FTLD or
PiD were excluded. Longitudinal clinical information
revealed that all FTLD and PiD cases had behavioural change
at onset. Nine out of 13 cases had no family history of
dementia or other neurological condition. Four of these cases
tested negative for tau gene abnormalities (no genetic
screening tests were found in the medical records of the
remaining cases). Four out of 13 cases had family members
with dementia. Two of these cases had a parent with dementia
and were negative in screening tests for tau gene mutations.
The other two cases had an elderly aunt or uncle with
dementia and one had records of a negative tau gene
screening test (the other case was not screened). We believe
that none of the cases examined had known tau gene
mutations. Control cases were without neurological or
neuropathological disease and had no family history of
disease. Case details, including diagnosis, age, post-mortem
delay and dementia duration, are given in Table 1. Non-
parametric Kruskal±Wallis tests were used to determine any
signi®cant group differences between these variables.
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 Tissue preparation
Each brain was weighed and the volume determined by ¯uid
displacement. Following ®xation for 14 days in neutral
buffered formalin, the cerebellum and brainstem were
separated from the cerebrum by sectioning through the
cerebral peduncles. The weight and volume of the cerebrum
were determined and the length of each hemisphere was
measured. Prior to sectioning, the superior frontal gyrus was
painted with coloured dyes as described previously (Harasty
et al., 1999). The cerebrum was embedded in 3% agarose and
sliced coronally at 3 mm intervals. The posterior surface of
each slice was photographed and printed in black and white at
31 magni®cation. For neuropathological diagnosis, blocks
from the limbic (amygdala, hippocampus and anterior
cingulate), frontal, parietal, temporal and occipital neocortex
and from the basal ganglia, diencephalon, brainstem and
cerebellum were sampled. Sections were cut and stained with
haematoxylin and eosin, the modi®ed Bielschowsky silver
stain and immunohistochemistry for tau-2 (mouse anti-human
tau; T5530 from Sigma, St Louis, MO, USA; diluted
1 : 10 000), a-synuclein (mouse anti-human a-synuclein;
18 0215 from Zymed Laboratories, South San Francisco, CA,
USA; diluted 1 : 200), ubiquitin (rabbit anti-cow ubiquitin;
Z0458 from Dako, Botany, Australia; diluted 1 : 200) and
phosphorylated neuro®lament (mouse anti-human phos-
phorylated neuro®lament; MAS330 from Seralab, Leicester,
UK; diluted 1 : 2000). Standard peroxidase visualization was
used with diaminobenzidine (Sigma) as the chromogen.
For detailed analysis of the glia, tissue blocks were
sampled from the superior frontal cortex and underlying
white matter and placed in 30% sucrose solution overnight.
Recent in vivo blood ¯ow and imaging studies have identi®ed
the superior frontal gyrus as the region most affected in FTD
(Sjogren et al., 2000). Serial 50 mm thick sections were cut on
a cryostat and consecutive free-¯oating sections were stained
immunohistochemically (Shepherd et al., 2000) for microglia
using antibodies for the major histocompatibility antigen II
(HLA-DR, mouse anti-human HLA-DR; M0775 from Dako;
diluted 1 : 1000) and the anti-macrophage scavenger receptor
(MSR; goat anti-macrophage scavenger receptor type 1
polyclonal antibody from Chemicon International,
Temecula, CA; diluted 1 : 5000). Two microglial markers
were required, as HLA-DR could not be used simultaneously
with tau antibodies to double-label tau-positive microglia.
Sections were also stained for astrocytes using an antibody
for glial ®brillary acidic protein (GFAP; rabbit anti-cow
GFAP; Z0334; Dako; diluted 1 : 750). Tau-containing
pathologies were detected using the AT8 antibody (mouse
Fig. 1 Representative photomicrographs of cases with PiD and FTLD demonstrating diagnostic
neuropathology. Scale bar in B is appropriate for A and D.( A) Tau-2 immunohistochemistry
demonstrating widespread Pick bodies in the CA1 of a PiD case. Insert shows phosphorylated
neuro®lament immunohistochemistry of a ballooned neuron in the lower cortical layers of a PiD case.
Scale in insert is 50 mm. (B) Modi®ed Bielschowsky silver stain demonstrating widespread Pick bodies
and the absence of any other neuropathology in the CA1 of a PiD case. (C) Haematoxylin and eosin stain
demonstrating microvacuolar degeneration in the upper cortical layers of the frontal cortex of an FTLD
case. (D) Modi®ed Bielschowsky silver stain of the frontal cortex of a case with FTLD, demonstrating the
absence of distinctive neuropathology.
Tau-positive glia in frontotemporal dementia 829
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 anti-human paired helical ®lament tau; MN1020; Pierce
Endogen, Chicago, IL, USA; diluted 1 : 10 000) and the tau-2
antibody (mouse anti-human tau-2; T5530; Sigma; diluted
1 : 20 000). AT8 antibody detects tau, which is phosphoryl-
ated at serines 202 and 205. In contrast, tau-2 antibody is
phosphorylation-independent, detecting tau with the epitope
proline 101 masked (Watanabe et al., 1992). Tau-2 localizes
tau with residues 92±108 in a serine conformation (found in
paired helical ®lament tau) and in an unfolded conformation
(found in reactive glia) (Watanabe et al., 1992).
Antigen retrieval using 4% aluminium chloride (AlCl3)
buffer was carried out on the tissue sections to maximize
proteinvisualization,asdescribedpreviously(Shepherdetal.,
2000). Brie¯y, tissue sections were rinsed in 4% AlCl3 and
microwaved (1000 W microwave) for 6 s on 80% power.
Sections were then washed in 0.1 M Tris buffer (0.1 M Tris
and 0.1% azide, pH 7.4) followed by 50% alcohol for 3 3 15
min. This was followed by a further wash in 50% alcohol with
3% H2O2 (20 min) before immunohistochemical staining.
Sections were incubated with 10% blocking serum before
incubation with the primary antibody overnight at 4°C.
Sections were washed in 0.1 M Tris±Triton (3 3 15 min;
0.1% Triton). Biotinylated secondary antibody (biotinylated
IgG; Vector Laboratories, Burlingame, CA, USA) was
applied and incubated at room temperature for 1 h. After
further washing for 3 3 15 min, sections were incubated in
Vectastain Elite ABC (Vector Laboratories) for 1 h and
washed for 3 3 15 min, and the peroxidase was visualized
with diaminobenzidine. Sections were then mounted onto
gelatinized slides, dehydrated through alcohol (70%, 90%, 2
3 100% for 5 min), cleared in xylene and coverslipped with
Depex. The speci®city of the immunohistochemical reactions
were tested by omitting the primary antisera. No peroxidase
reaction was observed in these test sections.
To determine the glial types containing tau, double-
labelling immuno¯uorescent experiments were performed.
Colocalization of tau with the immunohistochemical markers
used to identify speci®c populations of cells (see above) was
performed by mixing mouse and rabbit primary antibodies
prior to incubating with host-speci®c secondary ¯uorescent
antibodies (donkey anti-rabbit ¯uorescein from Amersham
Pharmacia Biotech, Sydney, Australia; diluted 1 : 50; donkey
anti-mouse rhodamine red from Jackson Immunoresearch
Laboratories, Medical Dynamics, Sydney, Australia; diluted
1 : 100). Double-labelled sections were analysed using an
Olympus BX51 ¯uorescence microscope ®tted with speci®c
®lter systems to view ¯uorescein (®lter U-MNIBA2),
rhodamine red (®lter U-MWIG2) and a wide-band ultraviolet
®lter (U-MWU2) for non-speci®c ¯uorescence.
Glia quantitation
The density of GFAP-positive astrocytic and HLA-DR-
positive microglia cell bodies contained within the 50 mm
thick sections was estimated by sampling three cortical strips
perpendicular to the pial surface (400 mm wide) and four
white matter samples (area of 400 3 400 mm) of the superior
frontal gyrus from each case at 3200 magni®cation using an
Olympus BH-2 microscope. We have shown previously that
such sampling methods are adequate for the quantitation of
cortical neuronal populations (Kril et al., 1997). The number
of glia cells within each sample was counted using inclusion
(upper and left) and exclusion (lower and right) borders. The
proportion of glia double-labelled with tau-2 and MSR
antibodies was determined in ®ve cortical and ®ve white
matter samples (400 3 400 mm) of the superior frontal gyrus
containing dense cellular labelling from each case at 3400
magni®cation using an Olympus BX51 ¯uorescence micro-
Table 1 Case details
Case Diagnosis Sex Onset age Disease duration Age at death Cause of death Post-mortem delay Brain weight
(M/F) (years) (years) (years) (h) (g)
1 FTLD M 43 8 51 Unknown 15.5 1037
2 FTLD M 52 2 54 Respiratory 22 1144
3 FTLD F 56 5 61 Disabilities 33 958
4 FTLD F 58 12 70 Disabilities 10 774
5 FTLD F 62 5 67 Heart disease 28 859
6 PiD F ± ± 64 Cardiorespiratory 72 1124
7 PiD M 51 16 67 Pneumonia 14 847
8 PiD F 58 7 65 Pneumonia ± 1060
9 PiD F 61 10 71 Pneumonia 5.5 848
10 PiD M 62 10 72 Disabilities 6 934
11 PiD M 64 5 69 Pneumonia 4 869
12 PiD F 65 11 76 Heart disease 9 750
13 PiD M 70 9 79 Unknown 24 1089
14 Control M ± ± 54 Blood loss 25 1397
15 Control M ± ± 61 Sepsis 10 1343
16 Control F ± ± 69 Heart disease 4 1403
17 Control F ± ± 75 Cancer 29 1036
18 Control F ± ± 77 Heart disease 26 1132
830 E. Scho®eld et al.
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 scope ®tted with speci®c ®lter systems (see above). Density
counts (C.K., J.J.K.) and the proportion of tau-positive glia
(E.S., C.E.S.) were veri®ed by two independent researchers
blind to case details. Variability in glial counts and the
proportions containing tau were <2% for each investigator,
with a correlation between investigators of 0.98.
Evaluation of cell loss for correlations
Because of the signi®cant differences in the overall amount
and rate of atrophy observed in different FTD cases (Chan
et al., 2001), neuronal density measures alone are insuf®cient
to determine the entire extent of cell loss when signi®cant
volume changes are occurring (Oorschot, 1994; Benes and
Lange, 2001) and the major focus of the glial reaction is the
white matter (Cooper et al., 1996; Kitagaki et al., 1997;
Nichol et al., 2001). For these reasons, two strategies were
adopted to determine the stage of disease regarding the degree
of neuronal loss.
(i) For each case, a relative severity rating was given based
on the degree of gross brain atrophy, incorporating both grey
and white matter changes. This was achieved by analysing
three standard coronal photographs approximately equidis-
tant through the brain, using methods similar to those devised
for the staging of Huntington's disease (Vonsattel et al.,
1985). The anterior and middle coronal sections incorporated
features and structures that are speci®cally vulnerable in FTD
(Fig. 2). Case variability was assessed, common patterns were
identi®ed and a scheme of disease severity was developed
(E.S., C.E.S.). Cases fell into four characteristic, progres-
sively more severe, stages of global atrophy (stage 1±4)
(Fig. 2). The validity of the scheme was tested using k
statistics for multiple raters (Fleiss, 1971). Five independent
researchers (C.K., J.J.K., G.M.H., H.McCann, H.Cartwright)
blind to case details determined the stage for each case with
near perfect agreement (k = 0.92; Landis and Kach, 1977).
The data show that this simple scheme was reliable and
reproducible for the cases examined.
(ii) The loss of large pyramidal neurons was estimated in
upper and lower cortical layers. The density of upper and
lower layer pyramidal neurons was estimated in ®ve random
samples (400 3 400 mm) within the upper and lower superior
frontal gyrus from each case at 3200 magni®cation using a
Zeiss Axioskop microscope. The number of large Nissl-
stained pyramidal neurons was counted (Fig. 3) and the
counts were veri®ed by three independent researchers blind to
case details (E.S., C.E.S., G.M.H.). Large pyramidal neurons
were identi®ed by their size (larger than the macroglia), shape
(pyramidal) and staining characteristics (less Nissl substance
in their cytoplasm compared with glia), and the number of
large pyramidal neurons within each sample was counted
using inclusion (upper and left) and exclusion (lower and
right) borders. Using this method, very small pyramidal
neurons and very atrophic, dysfunctional pyramidal neurons
were not counted. Variability was <5% for each investigator,
with a correlation between investigators of >0.9. To correct
for atrophy, the volume of the superior frontal gyrus was
calculated for each case using our standard published method
(Cullen et al., 1997; Harasty et al., 1999). Each coronal
photograph was overlaid randomly with a grid of 3848 points
(area 286 3 196 mm), and the number of points falling on the
superior frontal gyrus and the total number of points within
each brain slice were counted. The volume of the superior
frontal gyrus was calculated by multiplying the sum of the
points falling on this structure by the volume represented by
each point (volume/point = number of cerebrum points/
Fig. 2 Visual staging of the severity of atrophy in FTD. Shading
indicates severity of atrophy of each structure on the scale: none;
mild; moderate; severe. Cases fell into four characteristic,
progressively more severe stages of global atrophy (stages 1±4).
(Stage 1) Atrophy of the anterior frontal cortex and hippocampus.
(Stage 2) Additional atrophy of the orbitofrontal gyrus with mild
to moderate atrophy of the remaining frontal lobe and basal
ganglia. Mild atrophy of the posterior temporal cortex with
progression of hippocampal atrophy. (Stage 3) Gross atrophy of
the temporal pole and progression of temporal, frontal and
orbitofrontal atrophy affecting the underlying white matter. The
hippocampus is small but there is relative preservation of the
superior temporal gyrus. (Stage 4) Severe frontotemporal lobar
atrophy including the basal ganglia and thalamus. The
hippocampus and all temporal cortex and white matter are almost
completely atrophic.
Tau-positive glia in frontotemporal dementia 831
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 cerebrum volume, average 0.05 cm3, mean number of points
counted for each cerebrum 23 185 6 741). Repeated
measures gave a 1% maximum error with an inter-rater
error of <1% (J.K., G.H., H.McCann, H.Cartwright). The
density of large pyramidal cells was corrected for the volume
of the superior frontal gyrus and expressed as a percentage of
mean control values.
Statistics
Statistical analysis was performed using Statview (Abacus,
Berkeley, CA, USA). Means and standard deviations are
given for all variables and a P value of < 0.05 was taken as the
level of signi®cance. Non-parametric Kruskal±Wallis tests
were used to determine any signi®cant group differences
between demographic and cellular variables, and post hoc
Mann±Whitney U tests were used to determine any group
differences. Linear regressions were used to correlate disease
stage to demographic variables and cellular quantitation, and
to determine any linear relationship between the different
cellular parameters measured.
Results
Disease variability
As expected, there was a signi®cant difference between the
mean brain weights of the groups (H = 6.9, P = 0.03), those of
the FTLD and PiD cases being signi®cantly smaller than
Fig. 3 Validation that the staging scheme related to the degree of neuronal loss was tested by quantifying
pyramidal cell loss in thick sections stained with cresyl violet. Graphical representation of the association
between cell loss and disease stage (F). Scale bar is appropriate for all photomicrographs. (A) Density of
pyramidal neurons in controls (stage 0). (B) A signi®cant reduction in the number of large frontal
pyramidal neurons was seen at stage 1. A PiD case is shown. (C) By stage 2 all cases had nearly
complete loss of large pyramidal neurons and signi®cant gliosis. An FTLD case is shown. (D and E)N o
further reduction in large pyramidal cell number occurred at stage 3 (D, a PiD case) or 4 (E, an FTLD
case) but glia appear to have ¯ooded the cortex. (F) Regression analysis demonstrating the strong
relationship between cell loss and the stage of disease severity (R2 = 0.75 P < 0.0001).
832 E. Scho®eld et al.
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 those of controls (control, 1262 6 169 g, FTLD, 954 6 145 g,
P = 0.04; PiD, 940 6 136 g, P = 0.01). However, the degree
of atrophy did not differ between the FTLD and PiD cases
(post hoc P = 0.77), nor did their stage of disease (Table 2).
For PiD, the stage of gross atrophy correlated linearly with
disease duration (3±5 years between stages, R2 = 0.78,
P = 0.004), whereas for the FTLD cases the stage of gross
atrophy was more severe the earlier the age of onset (onset
differing by 5±7 years between stages, R2 = 0.62, P = 0.11).
The degree of pyramidal cell loss did not differ signi®-
cantly between FTLD and PiD (H = 11.2, P = 0.004, post hoc
P = 0.12). However, the degree of pyramidal cell loss varied
considerably across the stages in FTLD and PiD (Fig. 3). In
controls, the density of large pyramidal neurons did not differ
between layers 2, 3 and 5. In all FTD and PiD cases, there was
signi®cantly more pyramidal cell loss in cortical layer 2
(average 72% of control densities) compared with layers 3
and 5 (average 35±45% of control densities), with a strong
relationship between atrophy-corrected pyramidal cell loss
and the stage of disease severity (R2 = 0.75, P < 0.0001)
(Fig. 3F). The average reduction in large frontal pyramidal
neurons was 45 6 6% in stage 1 cases (H = 13.6, P = 0.009,
post hoc P = 0.03), with a further reduction of 32 6 8%
between stage 1 and the later stages (post hoc P values <0.05).
The loss of cortical pyramidal neurons appeared nearly
complete by stage 2 as no further reduction in pyramidal cell
number occurred from stage 2 onwards (average 776 8% cell
loss, post hoc P > 0.15). At this stage the cortex was virtually
devoid of neurons, but was packed with glial nuclei (Fig. 3C±
E). The data show similar patterns of cell loss between cases
with different underlying histopathology, and that the degree
of cell loss and therefore disease severity can be predicted
using a simple staging scheme.
Astroglia changes and relationship to disease
stage
As described previously (Dickson, 1998; Mann, 1998;
Komori, 1999; Arnold et al., 2000; Martin et al., 2001),
astrogliosis was substantial in both FTLD and PiD cases
(Fig. 4G±I), with higher average densities in PiD than in
FTLD (PiD, 2536 6 918/mm3; FTLD, 1512 6 342/mm3;
control, 208 6 66/mm3). GFAP-positive astrocyte density
differed signi®cantly between PiD and FTLD cases (post hoc
P = 0.46) but did not differ signi®cantly between these cases
and controls (H = 8.8, P = 0.01). As described previously
(Dickson, 1998; Komori, 1999), many astroglia contained
AT8 and tau-2 immunoreactivity in PiD (Fig. 4E, M±O), in
contrast to the absence of tau-immunoreactive astroglia in
FTLD (Fig. 4F, P±R). Both AT8 and tau-2 antibodies stained
®lamentous inclusions within the astrocytes (Fig. 4B, E),
often displacing the GFAP-positive ®brils within the
cytoplasm (Fig. 4M±O). In consecutive sections, the distri-
bution of these tau-positive astroglia was similar to that of
GFAP-positive astroglia in the same cases (Fig. 4B, E, H).
Double-labelling experiments revealed that 23 6 8% of
cortical GFAP-positive astroglia sampled were also tau-2-
positive in PiD (Fig. 4M±O). The density and cortical
distribution of both AT8- and tau-2-positive astroglia varied
similarly between cases, being largely absent at early stages
and maximal at stage 3 (Fig. 5A±H, Table 2).
Microglia changes and relationship to disease
stage
As described previously (Paulus et al., 1993; Arnold et al.,
2000), there was considerable microglial upregulation in the
Table 2 Summary of disease stage and glial changes in FTLD and PiD compared with controls
Case Diagnosis Disease Cortex White matter
stage
(0±4) GFAP+ astroglia AT8/tau-2+ astroglia HLA-R+ microglia Tau-2+ microglia
1 FTLD 4 ++ ± +++ ++
2 FTLD 2 ++ ± +++ ++
3 FTLD 4 + ± ++ +
4 FTLD 1 + ± ++ ++
5 FTLD 1 + ± ++ +
6 PiD 2 ± ± + ±
7 PiD 4 ++ + ++ ±
8 PiD 2 + ± ++ ±
9 PiD 3 +++ ++ ++ ±
10 PiD 2 +++ ++ ++ ±
11 PiD 1 + ± ++ ±
12 PiD 3 +++ +++ +++ ±
13 PiD 3 +++ ++ ++ ±
14 Control 0 ± ± ± ±
15 Control 0 ± ± ± ±
16 Control 0 ± ± ± ±
17 Control 0 ± ± ± ±
18 Control 0 ± ± ± ±
+ = mild increase, ++ = moderate increase, +++ = substantial increase.
Tau-positive glia in frontotemporal dementia 833
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 frontal cortex compared with controls (Figs 4J±L and 6D±F).
Many upregulated HLA-DR- and MSR-positive microglia
had distinctive phagocytic morphology (Figs 4K, L and 6E, F,
M, P). The amount of cortical microglial activation was
similar in FTLD and PiD (HLA-DR-positive microglia
density, PiD, 2616 6 1468/mm3; FTLD, 2303 6 1532/
mm3; control, 27 6 52/mm3; H = 6.7, P = 0.04, post hoc
P = 0.83). This was consistent for the white matter also, with
microglial upregulation similar between FTLD and PiD
(HLA-DR-positive microglia density, PiD, 4668 6 1731/
mm3;FTLD, 515661175/mm3;control,060/mm3;H=8.1,
P = 0.02, post hoc P = 0.92). However, twice as many
activated microglia were found in the white matter underlying
the frontal cortex in both disorders (Figs 4K, L and 6E, F, M,
P), indicating a preference for this response to concentrate in
the white matter, as described previously (Paulus et al., 1993;
Mann, 1998). Whereas the FTLD cases were largely devoid
of neuronal tau deposition, widespread tau-2-immunoreac-
tivity was observed in white matter microglia in most cases
(Table 2). In contrast, no AT8-positive microglia or other
cellular structures were observed in consecutively stained
sections (Fig. 6L). Also, no tau-positive microglia were
observed in PiD, despite high densities of HLA-DR-positive
microglia (Figs 4B, E, N and 6H, K, N). In consecutive
834 E. Scho®eld et al.
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 sections from the FTLD cases, the morphology and distribu-
tion of these microglia was similar to that of HLA-DR/MSR-
positive microglia in the same cases (Fig. 6F, I). The cellular
staining pattern of tau-2 was diffuse throughout the cytoplasm
of the microglia and did not appear ®brillar (Fig. 6I, Q).
Double-labelling experiments revealed that 35 6 14% of
white matter MSR-positive microglia sampled were also tau-
2-positive in FTLD (Fig. 6P±R). The tau-2-positive microglia
concentrated in the white matter of FTLD cases at stages 1
and 2 (Fig. 5I±N, Table 2), indicating early involvement in
the disease process.
Discussion
This report provides the ®rst direct comparison of the amount
of neuronal cell loss and gliosis between samples of cases
with PiD and FTLD. Our data indicate that the patterns of
gross atrophy (see also Mann and South, 1993) and the
amount of neuronal cell loss and microglial activation are
virtually identical between these two types of FTD, and that
these degenerative changes occur in unison. These data
suggest that microglial activation and neuronal loss are linked
in the pathogenesis of both types of FTD. These histopatho-
logical changes must be the primary factors underlying the
consistent patterns of frontotemporal atrophy and hypometa-
bolism characterizing FTD (Hodges and Miller, 2001;
McKhann et al., 2001).
As highlighted in recent reviews (Hodges and Miller, 2001;
McKhann et al., 2001), the different underlying histopathol-
ogies identi®ed in patients with FTD cannot be predicted in
life, and longitudinal studies show considerable heterogeneity
in the rate of degeneration between cases (Chan et al., 2001).
A standard progression over a relatively predictable time
course is yet to be determined. In the absence of such data, we
used the methods developed for staging Huntington's disease
(Vonsattel et al., 1985), a disorder with similarities regarding
disease variability in onset, progression and stage. By using
reliable patterns of gross atrophy, the amount of tissue
damage can be staged (stage correlated with the amount of
pyramidal cell loss) and early versus late events inferred. In
the limited number of cases sampled, the stage of disease was
related to the duration of the clinical syndrome for PiD,
validating the concept that the stages are progressive and
suggesting that this FTD phenotype may have a more
predictable disease course. The amount of neuronal degen-
eration correlated with disease stage and the degree of
microglial activation in both PiD and FTLD, linking these
phenomena to the time course of disease.
Few previous studies have quanti®ed the amount of
neuronal loss in either PiD (Hansen et al., 1988) or FTLD
(Arnold et al., 2000). In eight PiD cases, the frontal cortex
was thinned by an average of 42% compared with controls
and showed a 56% reduction in the density of medium to
large neurons, although great variability between cases was
found (Hansen et al., 1988). Neuronal density was reduced on
average by 45% in ®ve FTLD cases (Arnold et al., 2000).
These data are consistent with the results of the present study
comparing PiD and FTLD using atrophy-corrected cell
counts. As might be expected, our data indicate that neuronal
loss is more substantial if tissue loss is taken into account.
However, we also show considerable variability in neuronal
loss, this variability relating directly to the stage of the
disease process.
In addition to the similarities noted above, differences
other than those required for diagnostic differentiation were
found between the cases of PiD and FTLD. In particular, the
glial responses differentiated these two types of FTD.
Although not statistically signi®cant, more astrocytes were
observed in PiD compared with FTLD, and in PiD a large
proportion of these astrocytes contained abnormal phos-
phorylated tau depositions, as described previously (Komori,
1999; Berry et al., 2001). Tau-immunoreactive astrocytes
were not found in any of the FTLD cases. The lower average
number of astrocytes seen in FTLD may be due to their active
degeneration (Su et al., 2000; Martin et al., 2001; Nichol
et al., 2001), although levels of GFAP in the CSF are not
Fig. 4 Representative photomicrographs taken from the frontal cortex of control (A, D, G, J), PiD (B, E, H, K, M±O) and FTLD (C, F,
I, L, P±R) cases. Sections were stained immunohistochemically with antibodies against AT8 (A±C), tau-2 (D±F, N, Q), GFAP (G±I,
M, P) and HLA-DR (J±L). All scale bars are 50 mm and the scale bars in the right-hand panels are appropriate for the panels to their left.
(A±C) AT8 immunohistochemistry in a control (A), a PiD case (B) and an FTLD case (C). No neuritic AT8-positive pathology was seen
in controls (A) or FTLD (C). AT8-positive Pick bodies (B) and glial-like cells (arrows, B) were abundant within the cortex of PiD cases.
(D±F) Tau-2 immunohistochemistry in a control (D), a PiD case (E) and an FTLD case (F). No tau-2-positive pathology was seen in
controls (D) or FTLD (F). Tau-2-positive Pick bodies (arrowheads, E) and glial-like cells (arrows, E) were abundant within the cortex of
PiD cases. (G±I) GFAP immunohistochemistry in a control (G), a PiD case (H) and an FTLD case (I). GFAP-immunoreactive astrocytes
were occasionally present in the cortex of aged controls (G). Astrogliosis was substantial in the cortex of our PiD cases (H) and was
similar in distribution to the tau-positive glial structures seen in the same cases (B, E). Astrogliosis was also a feature of FTLD (I), albeit
to a lesser extent than in PiD (H). (J±L) HLA-DR immunohistochemistry in a control (J), a PiD case (K) and an FTLD case (L). HLA-
DR-immunoreactive microglia were not a feature of our control cases (J). HLA-DR-immunoreactive microglia were abundant in the
cortex of both our PiD (K) and FTLD (L) cases. (M±O) Double labelling using GFAP (M) and tau-2 (N) immunohistochemistry in a PiD
case. Non-speci®c auto¯uorescence is seen in O. GFAP-positive astrocytes were a signi®cant feature of the frontal cortex in PiD (M).
Many GFAP-positive astroglia were double-labelled with tau in PiD (arrows in M, N). These structures were not auto¯uorescent under
ultraviolet ®lters (O). (P±R) Double-labelling using GFAP (P) and tau-2 (Q) immunohistochemistry in an FTLD case. Non-speci®c
auto¯uorescence is seen in R. GFAP-positive astroglia were present throughout the cortex in FTLD (P). No tau-positive astroglia were
present in FTLD (Q). Arrowheads in R indicate auto¯uorescence as viewed under ultraviolet light.
Tau-positive glia in frontotemporal dementia 835
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 Fig. 5 Changes in glial densities at different disease stages in representative photomicrographs of the frontal cortex (A±H) and underlying
white matter (I±N) of PiD (A±H) and FTLD (I±N) cases. Sections were stained immunohistochemically with tau-2 (A±D and L±N),
GFAP (E±H) and HLA-DR (I±K). Scale bar is appropriate for all photomicrographs. (A±D) Tau-2-positive cortical astroglia are a
signi®cant feature of PiD. A = stage 1; B = stage 2; C = stage 3; D = stage 4. The density and cortical distribution of the tau-2-positive
astroglia varied between cases, being largely absent at early stages (A) and maximal at stage 3 (C). (E±H) The distribution and pattern of
tau-2-positive astroglia were similar to those of GFAP-positive astroglia in the same cases. E = stage 1; F = stage 2; G = stage 3; H = stage
4. (I±K) HLA-DR-positive microglia were maximal by stage 2 (J) in the white matter of FTLD cases. I = stage 1; J = stage 2; K = stage
4. (L±N) The tau-2-positive microglia were similar in pattern and distribution to HLA-DR-positive microglia and concentrated in stage 1
(L) and 2 (M), indicating early involvement in the disease process. L = stage 1; M = stage 2; N = stage 4. Many tau-2-positive microglia
had distinctive phagocytic morphology.
Fig. 6 Representative photomicrographs taken from the white matter underlying the frontal cortex of control (A, D, G, J), PiD (B, E, H,
K, M±O) and FTLD (C, F, I, L, P±R) cases. Sections were stained immunohistochemically with antibodies against GFAP (A±C),
HLA-DR (D±F), tau-2 (G±I, N, Q), AT8 (J±L) and MSR (M, P). All scale bars are 50 mm and the scale bars in the right-hand panels are
appropriate for the panels to their left. (A±C) GFAP immunohistochemistry in a control (A), a PiD case (B) and an FTLD case (C). No
GFAP-positive astroglia were seen in the white matter underlying the frontal cortex in controls (A). GFAP-positive astrocytes were
present throughout the white matter in PiD (B) and FTLD (C). (D±F) HLA-DR immunohistochemistry in a control (D), a PiD case (E)
and an FTLD case (F). Reactive microglia were not present in the white matter underlying the frontal cortex of controls (D).
HLA-DR-positive microglia were abundant throughout the white matter of PiD (E) and FTLD (F). G±I) Tau-2 immunohistochemistry in a
control (G), a PiD case (H) and an FTLD case (I). No tau-2 immunoreactivity was present in the white matter of controls (G). Punctate
tau-2-positive axonal deposits were a feature in the white matter in PiD (H). Whereas the FTLD cases were devoid of neuronal tau
deposition (Fig. 4F), widespread tau-2-immunoreactive microglia were observed in the white matter (I). These were similar to the
HLA-DR-immunoreactive microglia seen in the same cases (F). (J±L) AT8 immunohistochemistry in a control (J), a PiD case (K) and an
FTLD case (L). No AT8-positive pathology was seen in the white matter of controls (J) or FTLD (L) cases. Punctate AT8-positive axonal
deposits were a feature in the white matter in PiD (K). (M±O) Double labelling using MSR (M) and tau-2 (N) immunohistochemistry in a
PiD case. Non-speci®c auto¯uorescence is seen in O. MSR-positive microglia were present throughout the white matter in PiD (M)i na
distribution and density similar to those of the HLA-DR-positive microglia (E). No microglia were auto¯uorescent (O) or double-labelled
with tau-2 in PiD (N). (P±R) Double labelling using MSR (P) and tau-2 (Q) immunohistochemistry in an FTLD case. Non-speci®c
auto¯uorescence is seen in R. MSR-immunoreactive microglia were present throughout the white matter in FTLD cases (P)i na
distribution and density similar to those of the HLA-DR-positive microglia (F). Many MSR-positive microglia were also immunoreactive
for tau-2 (arrows in P, Q). Microglia were not auto¯uorescent under ultraviolet ®lters (R).
836 E. Scho®eld et al.
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
6
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 changed (Wallin et al., 1996). Increased CSF levels of the
astrocytic calcium-binding protein s100b in FTD (Green
et al., 1997) support astroglia upregulation in this disorder. In
PiD, astrocytic tau differs signi®cantly from the neuronal tau
found in Pick bodies, as it is made of four- rather than three-
repeat isoforms (Arai et al., 2001). Four-repeat tau isoforms
also accumulate in astrocytes in areas undergoing degener-
ation in familial FTD with tau gene mutations and in sporadic
corticobasal degeneration and progressive supranuclear palsy
(Komori, 1999; Arai et al., 2001; Berry et al., 2001). This
suggests a link between the accumulation of astrocytic tau
and neuronal tau, but highlights the fact that signi®cantly
different pathogenic processes must occur in neurons in PiD
for three- rather than four-repeat tau to accumulate (Arai
et al., 2001).
Microglial activation was identical in both PiD and FTLD.
Signi®cant microglial activation has been described previ-
ously (Paulus et al., 1993; Cooper et al., 1996; Hollister et al.,
1997; Arnold et al., 2000) and both neurons and astrocytes
have signi®cant complement immunostaining (Yasuhara
et al., 1994; Singhrao et al., 1996), suggesting a classical
immune response. However, there is no evidence of
lymphocytic in®ltration using routine (Dickson, 1998;
Mann, 1998) or cell-speci®c (Singhrao et al., 1996;
Tau-positive glia in frontotemporal dementia 837
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 Hollister et al., 1997) stains. It is well known that activation
of microglia occurs in response to non-immunological
stimuli, including cerebral ischaemia and neuronal cell
death (Kreutzberg, 1996). Of course, both frontotemporal
atrophy and hypoperfusion are diagnostic for FTD (Talbot
et al., 1995; Miller and Gearhart, 1999; Charpentier et al.,
2000; McKhann et al., 2001; Santens et al., 2001) and may be
the main initiators of the microglia response observed.
However, as noted previously (Cooper et al., 1996; Nichol
et al., 2001), the region containing the highest density of
activated microglia was the white matter underlying the
cortex rather than the cortical grey matter. The concentration
of activated microglia in the white matter suggests that cell
structures in this site are preferentially undergoing damage.
There is in vivo evidence for prominent T2- and proton
density-weighted magnetic resonance change in the frontal
white matter in FTD (Kitagaki et al., 1997; Larsson et al.,
2000), with the observation that the increased signal intensity
at this site is a sensitive diagnostic marker (Kitagaki et al.,
1997). Our data suggest that this observed change is likely to
re¯ect activation of white matter microglia. Such an immune
response within the white matter is reminiscent of neuro-
degenerative demyelinating disorders.
A major difference in the microglial response between
cases of PiD and FTLD was that tau-2-immunoreactive,
upregulated microglia were observed in FTLD but not PiD.
The density of such microglia in FTLD was high (Figs 5I±K
and 6I, Q). It has been suggested that microglial tau is of a
particular conformational form not present in the pathology
of other glial types (Berry et al., 2001), and possibly could be
due to Fc binding of tau (Komori, 1999). It has been shown
that tau associated with glycolipids is an extremely potent
antibody-independent activator of the classical complement
pathway [better than IgG itself (Shen et al., 2001)] and that
activated microglia accumulate around complement-immu-
noreactive tau-aggregates (Imamura et al., 2001). Activated
tau-2-positive microglia have been reported previously in
small numbers in subcortical grey matter structures in
Alzheimer's and Lewy body diseases (Odawara et al.,
1995), progressive supranuclear palsy and corticobasal
degeneration (Berry et al., 2001). In Alzheimer's disease,
large numbers of mainly resting cortical microglia concen-
trate tau in an unusual conformational form (Ghoshal et al.,
2001), although the relationship of this type of tau to the
expression of an immune response in microglia is unknown,
particularly as many of these cells appear quiescent (Ghoshal
et al., 2001). In contrast, the tau-2 immunoreactivity we have
documented in FTLD occurred in a proportion of activated
microglia largely within the white matter, and was not
observed in PiD. This strongly suggests an association
between this non-®brillar tau and a white matter immune
response in FTLD. Con®rmation of this ®nding in more cases
is now required. In experimental allergic encephalomyelitis
and multiple sclerosis, activated microglia are thought to play
a key role in terminating T-cell responses to self antigens
(Perry, 1998). In this situation the microglia present antigen
in a manner that does not induce lymphocyte proliferation,
but actively induces a new state in the surveillance T-cells
and results in apoptosis (Sedgwick, 1995; Perry, 1998). The
activation of microglia in the FTD cases examined may be
similar but associated with different self antigens.
Tau protein concentrates in axons (Binder et al., 1985) and
several studies suggest that an impairment in axonal transport
may play a role in both PiD (Nakamura et al., 1994; Probst
et al., 1996) and FTLD (Zhou et al., 1998). In addition to
complement (Yasuhara et al., 1994; Singhrao et al., 1996),
non-phosphorylated and hyperphosphorylated tau, phos-
phorylated neuro®lament and kinesin aggregate in Pick
bodies, some neurons and axons in PiD (Nakamura et al.,
1994; Probst et al., 1996; Dickson, 1998; King et al., 2001),
whereas in FTLD non-phosphorylated tau and neuro®laments
accumulate in axonal spheroids in the neuropil (Zhou et al.,
1998). Tau regulates the attachment of vesicles and
organelles to microtubules and their detachment from
microtubules by interacting with microtubule-binding
ATPases (Ebneth et al., 1998; Trinczek et al., 1999;
Almenar-Queralt and Goldstein, 2001) in a phosphoryl-
ation-dependent manner (Flaherty et al., 2000). The local
arrest of axoplasmic transport is associated with microtubule
disruption and eventually results in local breakdown of the
axolemma and the formation of end-bulbs (Povlishock and
Jenkins, 1995). Disruption of the dynamics between tau and
microtubules has been proposed as the major mechanism of
neurodegeneration in familial FTD cases with tau gene
mutations (Spillantini et al., 1998; Lee et al., 2001), and the
location and type of microglia response observed in both PiD
and FTLD would suggest that axonal disruption is also
important in these types of FTD.
The present study provides evidence linking the major
histopathological forms of FTD to abnormalities associated
with tau deposition in regions undergoing neurodegeneration.
The present data are consistent with different cellular
mechanisms of axonal tau dysfunction leading to neurode-
generation. Hyperphosphorylated neuronal and macroglial
tau deposition underlies the degeneration in PiD, while tau-2-
positive microglia appear related to the primary structural
damage in FTLD. This suggests that a proportion of FTD
cases may have a dominant in¯ammatory response to tau. If
con®rmed in larger cohorts, this ®nding has signi®cant
therapeutic implications.
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